SPRY
ARS Pharmaceuticals, Inc.
$8.99
+5.02%
$934.4M
No data for this timeframe.
Vol
Market Cap$934.4M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders6 funds
Inst. Value$64.9M
Inst. Activity1 buys / 2 sells
SEC Reports4
Press Releases2
Recent Activity
May 15, 2026
SEC
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M (up 184% YoY from $8.0M) and a net loss of $60.6M ($0.61/sh
8-K — Impact 5/10
May 15, 2026
SEC
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M, beating the $22.1M consensus, with neffy U.S. net product
PRESS-RELEASE — Impact 6/10
May 13, 2026
SEC
ARS Pharmaceuticals appointed Donn Casale as President effective June 1, 2026, replacing CEO Richard Lowenthal who previ
8-K — Impact 2/10
Inst.
BANK OF AMERICA CORP — ADD
482,084 shares ($5.6M)
Inst.
FMR LLC — TRIM
398,959 shares ($4.6M)
Jun 8, 2026
short_volume
Short Volume: SPRY — 59.8% short (0.5M / 0.9M)
Short: 538,252 | Exempt: 1,676 | TRF Vol: 900,174 | Short Ratio: 59.8% | Off-exchange volume (dark p
Mar 27, 2026
Press
ARS Pharmaceuticals announced FDA approval to remove age restrictions from the prescribing information for neffy 1 mg (e
Impact 7/10
Mar 9, 2026
Press
ARS Pharmaceuticals reported full-year 2025 revenue of $84.3 million, driven by $72.2 million in U.S. net product revenu
Impact 6/10
Price Targets
$28.80
+206.1% upside
Strong Buy
Current $9.41
Low $25.00
Median $30.00
High $32.00
5 analysts
$25.00
$32.00
Analyst Ratings
5Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.53 ▼ -23.3% | $-0.61 — $-0.47 | -15% YoY | 3 |
| Next Q | $-0.33 ▼ -38.9% | $-0.40 — $-0.20 | 37% YoY | 3 |
| Current FY | $-1.76 ▼ -12.3% | $-2.05 — $-1.45 | -1% YoY | 4 |
| Next FY | $-0.96 ▼ -26.4% | $-1.41 — $-0.44 | 46% YoY | 4 |
Latest Reports
NEUTRAL
8-K
5/10
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M (up 184% YoY from $8.0M) and a net loss of $60.6M ($0.61/sh
May 15, 2026
BEARISH
PRESS-RELEASE
6/10
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M, beating the $22.1M consensus, with neffy U.S. net product
May 15, 2026
BULLISH
Press
7/10
ARS Pharmaceuticals announced FDA approval to remove age restrictions from the prescribing information for neffy 1 mg (e
Mar 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $40.9M | — |
| MORGAN STANLEY | $6.4M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $6.4M | NEW |
| BANK OF AMERICA CORP | $5.6M | ADD |
| FMR LLC | $4.6M | TRIM |
6 institutional holders with $64.9M total value (5,567,769 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,509,174 | $40.9M | 63.0% | — |
| 2 | MORGAN STANLEY | 552,364 | $6.4M | 9.9% | ADD +82.6% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 550,932 | $6.4M | 9.9% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 482,084 | $5.6M | 8.7% | ADD +77.2% |
| 5 | FMR LLC | 398,959 | $4.6M | 7.2% | TRIM -46.3% |
| 6 | WELLS FARGO & COMPANY/MN | 74,256 | $865.1K | 1.3% | ADD +43.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 272,026 | 482,084 | +77.2% | $5.6M | 2025-Q4 |
| FMR LLC | TRIM | 742,508 | 398,959 | -46.3% | $4.6M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 72,177 | 0 | -100.0% | $0.00 | 2025-Q4 |
| FMR LLC | TRIM | 1,567,010 | 742,508 | -52.6% | $7.5M | 2025-Q3 |
| MORGAN STANLEY | ADD | 383,616 | 700,414 | +82.6% | $7.0M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 72,177 | — | $725.4K | 2025-Q3 |
| FMR LLC | ADD | 990,860 | 1,567,010 | +58.1% | $27.3M | 2025-Q2 |
| UBS Group AG | ADD | 591,182 | 866,935 | +46.6% | $15.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 444,703 | 325,352 | -26.8% | $5.7M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 10,771 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | TRIM | 1,012,701 | 591,182 | -41.6% | $7.4M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 41,701 | 59,647 | +43.0% | $750.4K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 98,078 | 10,771 | -89.0% | $135.5K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 416,299 | 1,047,656 | +151.7% | $11.1M | 2024-Q4 |
| UBS Group AG | DOUBLED | 109,882 | 1,012,701 | +821.6% | $10.7M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 638,622 | 432,603 | -32.3% | $4.6M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 28,340 | 41,701 | +47.1% | $439.9K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 15,800 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 133,806 | 638,622 | +377.3% | $9.3M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 423,947 | — | $6.1M | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
5/10
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M (up 184% YoY from $8.0M) and a net loss
May 15, 2026
BEARISH
PRESS-RELEASE
6/10
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M, beating the $22.1M consensus, with nef
May 15, 2026
NEUTRAL
8-K
2/10
ARS Pharmaceuticals appointed Donn Casale as President effective June 1, 2026, replacing CEO Richard
May 13, 2026
NEUTRAL
PRESS-RELEASE
4/10
ARS Pharmaceuticals reported Q4 2025 EPS of -$0.42, beating consensus of -$0.54 by 21.5%. The compan
May 7, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 5 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$28.80 mean target
+206.1% upside
Strong Buy (1.00)
$25.00 Low
$32.00 High
| Metric | Value |
|---|---|
| Current Price | $9.41 |
| Target Low | $25.00 |
| Target Mean | $28.80 |
| Target Median | $30.00 |
| Target High | $32.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.53 | $-0.61 | $-0.47 | -15.2% | -23.3% | 0↑ 2↓ | $0.0B | 100.6% | 3 |
| Next Q 2026-09-30 |
$-0.33 | $-0.40 | $-0.20 | 36.5% | -38.9% | 0↑ 1↓ | $0.1B | 57.9% | 3 |
| Current FY 2026-12-31 |
$-1.76 | $-2.05 | $-1.45 | -1.1% | -12.3% | 0↑ 1↓ | $0.1B | 77.2% | 4 |
| Next FY 2027-12-31 |
$-0.96 | $-1.41 | $-0.44 | 45.6% | -26.4% | 0↑ 3↓ | $0.3B | 83.2% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.530 | |
| 7d ago | $-0.530 | |
| 30d ago | $-0.430 | -0.100 |
| 60d ago | $-0.437 | -0.093 |
| 90d ago | $-0.540 | +0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 6 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
short_volume
Short Volume: SPRY — 59.8% short (0.5M / 0.9M)
Short: 538,252 | Exempt: 1,676 | TRF Vol: 900,174 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: SPRY — 73.2% short (0.4M / 0.6M)
Short: 407,065 | Exempt: 2,016 | TRF Vol: 555,852 | Short Ratio: 73.2% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: SPRY — 59.1% short (0.5M / 0.9M)
Short: 514,253 | Exempt: 0 | TRF Vol: 869,570 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: SPRY — 70.1% short (0.6M / 0.8M)
Short: 567,683 | Exempt: 2,800 | TRF Vol: 809,462 | Short Ratio: 70.1% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: SPRY — 85.1% short (1.0M / 1.2M)
Short: 1,010,801 | Exempt: 610 | TRF Vol: 1,187,430 | Short Ratio: 85.1% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: SPRY — 71.1% short (0.7M / 1.0M)
Short: 733,180 | Exempt: 1,590 | TRF Vol: 1,031,584 | Short Ratio: 71.1% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: SPRY — 66.2% short (0.4M / 0.7M)
Short: 447,275 | Exempt: 0 | TRF Vol: 675,272 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: SPRY — 67.2% short (0.6M / 1.0M)
Short: 649,395 | Exempt: 19,184 | TRF Vol: 965,862 | Short Ratio: 67.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
earnings
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
<p align="center"><em>Q1 2026 total revenue of $22.7 million including </em><strong><em>neffy</em></strong><sup><em>®</em></sup><em> (epinephrine nasa
May 15, 2026
earnings_calendar
SPRY Q1 2026 Earnings After Market Close — 2026-05-15
May 15, 2026
short_volume
Short Volume: SPRY — 70.0% short (0.8M / 1.2M)
Short: 849,648 | Exempt: 42,737 | TRF Vol: 1,214,286 | Short Ratio: 70.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: SPRY — 65.2% short (0.6M / 0.9M)
Short: 613,033 | Exempt: 0 | TRF Vol: 940,808 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_interest
FTD: SPRY — 75,516 shares ($0.6M) failed to deliver
Settlement: 20260514, Price: $8.01, FTD Value: $604,883.16, ARS PHARMACEUTICALS, INC. COMM
May 13, 2026
short_volume
Short Volume: SPRY — 59.2% short (0.5M / 0.8M)
Short: 481,396 | Exempt: 1,370 | TRF Vol: 812,784 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: SPRY — 57.0% short (0.3M / 0.5M)
Short: 291,999 | Exempt: 704 | TRF Vol: 512,597 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
Clinical Trial
Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares
Phase Phase 2 — COMPLETED